MRI Habitat-Directed Radiation for the Treatment of High-Grade Soft Tissue Sarcoma

Inclusion Criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Age >= 18 years
• For women of childbearing potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 52 weeks after the end of radiation
• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner 52 weeks after radiation
• Agreement to adhere to Lifestyle Considerations throughout study duration
• Pathologically (histologically or cytologically) proven diagnosis of high-grade (grade 2 or 3) STS of the deep trunk and/or extremity. Clinical evidence should be documented, and may consist of pathology or imaging, and should be sufficient to estimate the size of the primary (for T stage)
• Primary site deemed resectable prior to the start of trial
• American Joint Committee on Cancer (AJCC) 8th edition staging T1-4 N0 M0, no evidence of distant metastases
• Patients must have clinically or radiographically evident measurable disease at the primary site
• Pre-RT MRI within 4 weeks of the start of RT
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3
• Deemed a surgical candidate
• Patient agrees to blood and plasma preservation for future analysis

Exclusion Criteria

• Contraindications to an MRI
• Positive urine pregnancy test
• Gross total excision of primary STS, including an unplanned excision
• Superficial sarcoma located primarily in the subcutaneous or cutaneous tissue
• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
• Patients with a medical condition or social situation that, at the discretion of the principal investigator (PI), would preclude them from completion of the trial